TrialJournal of gastroenterology2017

Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma: Japanese subgroup analysis of the REACH trial.

Masatoshi Kudo et al.PubMed ↗Publisher ↗

No numbers read from the abstract.